Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Stryker Says FDA Warnings From 2007 Addressed

By Pharmaceutical Processing | March 24, 2010

KALAMAZOO, Mich. (AP) — The Food and Drug Administration has told Stryker Corp. that it has taken sufficient action to fix problems at its facility in Mahwah, N.J., the medical implant maker said Tuesday.

The company received a warning letter in 2007 from the FDA after a six-week inspection of the facility, which houses manufacturing operations, research and development and administrative offices.

Later, federal regulators ordered the company to fix a host of long-standing problems in its manufacturing of hip replacement parts, which triggered multiple patient complaints and forced some patients to have follow-up surgeries.

Problems included improper fitting of hip implants that caused bone fractures. Patients had also complained about pain, difficulty walking, squeaky joints and uneven wear or breaking of implant parts.

Some parts of the facility were found to be contaminated with disease-causing germs, including “clumps and clusters” of a form of Staphylococcus bacteria.

The company said Tuesday that after a follow-up inspection by the FDA in 2009 and additional corrective actions, it was informed the issues had been adequately addressed and no further formal corrective actions were required.

The resolution of the issues “is another important step in demonstrating our firm commitment to significantly transforming our quality systems,” CEO Stephen MacMillan said in a statement.

“The investments we have made, and will continue to make, are resulting in solid progress toward our goals,” he said.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE